{
    "clinical_study": {
        "@rank": "127714", 
        "arm_group": {
            "arm_group_label": "E/C/F/TAF", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive E/C/F/TAF STR once daily with food"
        }, 
        "brief_summary": {
            "textblock": "This study is to confirm the dose and evaluate the pharmacokinetics, safety, tolerability,\n      and antiviral activity of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide\n      (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment\n      naive adolescents. Antiviral activity will be determined by the achievement of HIV-1 RNA <\n      50 copies/mL at Weeks 24 and 48."
        }, 
        "brief_title": "Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acquired Immune Deficiency Syndrome (AIDS)", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following inclusion criteria to be eligible for\n        participation in this study. Subjects with screening results that do not meet eligibility\n        criteria will not be allowed to rescreen:\n\n          -  12 years to < 18 years of age at Baseline\n\n          -  Weight greater than or equal to 35 kg (77 lbs)\n\n          -  Subjects able to give written assent prior to any screening evaluations\n\n          -  Parent or guardian able to give written informed consent prior to any screening\n             evaluations and willing to comply with study requirements\n\n          -  Plasma HIV-1 RNA levels of > 1,000 copies/mL at Screening (Roche COBAS TaqMan v2.0)\n\n          -  CD4+ cell count > 100 cells/microliter\n\n          -  Screening genotype report shows sensitivity to EVG, FTC and TFV\n\n          -  Adequate renal function\n\n          -  Clinically normal ECG\n\n          -  Documented screening for active pulmonary tuberculosis per local standard of care\n             within 6 months of a Screening visit.\n\n          -  Hepatic transaminases less than or equal to 5 x upper limit of normal\n\n          -  Total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin\n\n          -  Adequate hematologic function\n\n          -  No prior use of any approved or experimental anti-HIV-1 drug for any length of time\n\n          -  Negative serum pregnancy test\n\n          -  Females of childbearing potential must agree to utilize highly effective\n             contraception methods or be non-heterosexually active or practice sexual abstinence\n             from Screening throughout the duration of study treatment and for 30 days following\n             discontinuation of investigational medicinal product.\n\n          -  Female subjects who utilize hormonal contraceptive as one of their birth control\n             methods must have used the same method for at least three months prior to study\n             dosing.\n\n          -  Male subjects must agree to utilize highly effective contraception methods during\n             heterosexual intercourse or be non-heterosexually active, or practice sexual\n             abstinence from Baseline throughout the study period and for 30 days following\n             discontinuation of investigational medicinal product.\n\n          -  Able to swallow oral tablets\n\n          -  Must be willing and able to comply with all study requirements\n\n          -  Life expectancy > 1 year\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following exclusion criteria are not to be enrolled in this\n        study.\n\n          -  A new AIDS defining condition diagnosed within the 30 days prior to Screening\n\n          -  Positive Hepatitis C antibody\n\n          -  Positive Hepatitis B surface antigen or other evidence of active hepatitis B virus\n             infection.\n\n          -  Prior treatment with any approved or investigational or experimental anti HIV-1 drug\n             for any length of time\n\n          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months\n             of the Screening visit.\n\n          -  Anticipated to require rifamycin treatment for mycobacterial infection while\n             participating in the study.\n\n          -  Subjects experiencing decompensated cirrhosis\n\n          -  Pregnant or lactating subjects\n\n          -  Have an implanted defibrillator or pacemaker\n\n          -  Have any serious or active medical or psychiatric illness which, in the opinion of\n             the Investigator, would interfere with subject treatment, assessment, or compliance\n             with the protocol.\n\n          -  Current alcohol or substance abuse judged by the Investigator to potentially\n             interfere with subject compliance.\n\n          -  Have history of significant drug sensitivity or drug allergy.\n\n          -  Known hypersensitivity to the study drugs, the metabolites or formulation excipients\n\n          -  Have been treated with immunosuppressant therapies or chemotherapeutic agents within\n             3 months of study Screening or expected to receive these agents during the study\n\n          -  A history of malignancy within the past 5 years (prior to Screening) or ongoing\n             malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or\n             resected, non-invasive cutaneous squamous carcinoma.\n\n          -  Active, serious infections (other than HIV-1 infection) requiring parenteral\n             antibiotic or antifungal therapy within 30 days prior to Baseline.\n\n          -  Have previously participated in an investigational trial involving administration of\n             any investigational agent within 30 days prior to the study dosing.\n\n          -  Participation in any other clinical trial without prior approval from sponsor is\n             prohibited while participating in this trial.\n\n          -  Subjects receiving ongoing therapy with any of the medications in the table below,\n             including drugs not to be used with EVG, COBI, FTC, tenofovir disoproxil fumarate\n             (TDF) and TAF; or subjects with any known allergies to the excipients of E/C/F/TAF\n             STR tablets."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854775", 
            "org_study_id": "GS-US-292-0106", 
            "secondary_id": "2013-002780-26"
        }, 
        "intervention": {
            "arm_group_label": "E/C/F/TAF", 
            "description": "E/C/F/TAF STR tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)", 
            "intervention_name": "E/C/F/TAF", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Tenofovir", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adolescents", 
            "HIV-1", 
            "HIV", 
            "Treatment-naive"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "562-933-8590"
                }, 
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Miller's Children Hospital"
                }, 
                "investigator": {
                    "last_name": "Jag Batra, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "510-869-8400"
                }, 
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Alta Bates Summit Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Burack, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "303-724-3447"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Children's Hospital Colorado"
                }, 
                "investigator": {
                    "last_name": "Elizabeth McFarland, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "202-476-2083"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20852"
                    }, 
                    "name": "Children's National Medical Center"
                }, 
                "investigator": {
                    "last_name": "Natella Rakhmanina, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "813-259-8800"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "University of South Florida - Department of Pediatrics"
                }, 
                "investigator": {
                    "last_name": "Carina Rodriguez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "404-727-4972"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Rana Chakraborty, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "212-263-6513"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York University"
                }, 
                "investigator": {
                    "last_name": "William Borkowsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "315-464-6331"
                }, 
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical Center"
                }, 
                "investigator": {
                    "last_name": "Leonard Weiner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Coleen Cunningham, MD", 
                    "phone": "919-668-4851"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Coleen Cunningham, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "901-495-5067"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "St. Jude Children's Research Hospital"
                }, 
                "investigator": {
                    "last_name": "Aditya Gaur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico", 
                        "state": "Jalisco", 
                        "zip": "44280"
                    }, 
                    "name": "Hospital Civil de Gualdalajara Fray Antonio Alcalde"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "phone": "+021 650 6726"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7925"
                    }, 
                    "name": "Desmond Tutu HIV Foundation"
                }, 
                "investigator": {
                    "last_name": "Catherine Orell", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+021868399012"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7646"
                    }, 
                    "name": "Be Part Yoluntu Centre"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Hellstrom", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+011 27-342182092"
                }, 
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "South Africa", 
                        "zip": "3000"
                    }, 
                    "name": "Mpati Medical Centre"
                }, 
                "investigator": {
                    "last_name": "Jan Fourie", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+011 27 31 309 3245"
                }, 
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4001"
                    }, 
                    "name": "Gulam Latiff Private Practice"
                }, 
                "investigator": {
                    "last_name": "Gulam Latiff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+011-2711 276 8800"
                }, 
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2092"
                    }, 
                    "name": "Clinical HIV Research Unit"
                }, 
                "investigator": {
                    "last_name": "Mohammed Rassool", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+011 27 11 470 9168"
                }, 
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2112"
                    }, 
                    "name": "Rahima Moosa Mother and Child Hopsital"
                }, 
                "investigator": {
                    "last_name": "Renate Strehlau", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+011-27-11-989-9700"
                }, 
                "facility": {
                    "address": {
                        "city": "Soweto", 
                        "country": "South Africa", 
                        "zip": "2013"
                    }, 
                    "name": "Perinatal HIV Research Unit"
                }, 
                "investigator": {
                    "last_name": "Avy Violari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "02 652 3040", 
                    "phone_ext": "134"
                }, 
                "facility": {
                    "address": {
                        "city": "Pathumwan", 
                        "country": "Thailand", 
                        "state": "Bangkok", 
                        "zip": "10330"
                    }, 
                    "name": "The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)"
                }, 
                "investigator": {
                    "last_name": "Wasana Pasitsuebsai, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "043 34 88 32"
                }, 
                "facility": {
                    "address": {
                        "city": "Muang", 
                        "country": "Thailand", 
                        "state": "Khon Kaen", 
                        "zip": "40002"
                    }, 
                    "name": "Department of Pediatrics, Faculty of Medicine, Khon Kaen University"
                }, 
                "investigator": {
                    "last_name": "Pope Kosalaraksa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+66 383 255 90"
                }, 
                "facility": {
                    "address": {
                        "city": "Chonburi", 
                        "country": "Thailand", 
                        "zip": "20110"
                    }, 
                    "name": "Queen Savang Vadhana Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Wicharn Luesomboon", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "phone": "+256414201148"
                }, 
                "facility": {
                    "address": {
                        "city": "Lubowa Hill", 
                        "country": "Uganda", 
                        "state": "Kampala", 
                        "zip": "PO Box 10005"
                    }, 
                    "name": "Joint Clinical Research Centre"
                }, 
                "investigator": {
                    "last_name": "Hilda Kizito, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Mexico", 
                "South Africa", 
                "Thailand", 
                "Uganda"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents", 
        "overall_contact": {
            "email": "skanda.goudar@gilead.com", 
            "last_name": "Skanda Goudar", 
            "phone": "650-524-4274"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Sean Bennett, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)\nAUClast is defined as the concentration of drug from time zero to the last quantifiable concentration", 
                "measure": "Plasma pharmacokinetics (PK) parameter of EVG as measured by AUCtau and PK parameter of TAF as measured by AUClast", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 4"
            }, 
            {
                "description": "Treatment-emergent serious adverse events and adverse events will be summarized.", 
                "measure": "Incidence of treatment-emergent serious adverse events and all treatment-emergent adverse events", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with plasma HIV-1 RNA < 50 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Percentage of subjects with plasma HIV-1 RNA < 400 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Change from baseline in plasma log10 HIV-1 RNA (copies/mL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Change from baseline in CD4+ cell count (cells/\u03bcL) and percentage", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval\nCmax is defined as the maximum observed concentration of drug in plasma\nVz is defined as the volume of distribution of the drug\nAUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)", 
                "measure": "PK parameters of EVG as measured by Ctau, Cmax, apparent clearance, and apparent Vz, PK parameters of TAF as measured by Cmax, apparent clearance, and apparent Vz, and PK parameters of FTC, tenofovir (TFV), and COBI as measured by AUCtau, Cmax, and Ctau", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 4"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}